Efficacy and Tolerability of Accelerated-Dose Low-Molecular-Weight Iron Dextran (Cosmofer) in Patients with Chronic Kidney Disease

2012 ◽  
Vol 35 (1) ◽  
pp. 69-74 ◽  
Author(s):  
M. Cooke ◽  
A. Lamplugh ◽  
S. Naudeer ◽  
M. Edey ◽  
S. Bhandari
Keyword(s):  
Chronic Kidney Disease ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Low Molecular Weight ◽  
Iron Dextran ◽  
Low Molecular Weight Iron

scholarly journals Accelerated total dose infusion of low molecular weight iron dextran is safe and efficacious in chronic kidney disease patients

QJM ◽  
2010 ◽  
Vol 104 (3) ◽  
pp. 221-230 ◽  
Author(s):  
S. Sinha ◽  
D. Chiu ◽  
G. Peebles ◽  
P. Swoboda ◽  
S. Kolakkat ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Total Dose ◽  
Low Molecular Weight ◽  
Iron Dextran ◽  
Dose Infusion ◽  
Low Molecular Weight Iron

COMPARISON OF INTRAVENOUS IRON SUCROSE VERSUS LOW-MOLECULAR-WEIGHT IRON DEXTRAN IN CHRONIC KIDNEY DISEASE

2009 ◽  
Vol 35 (2) ◽  
pp. 67-73 ◽  
Author(s):  
Smeeta Sinha ◽  
Diana Y.Y. Chiu ◽  
George Peebles ◽  
Shabeer Kolakkat ◽  
Elizabeth Lamerton ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Intravenous Iron ◽  
Iron Sucrose ◽  
Low Molecular Weight ◽  
Iron Dextran ◽  
Low Molecular Weight Iron

Electrophoretic patterns of proteinuria in feline spontaneous chronic kidney disease

2019 ◽  
Vol 22 (2) ◽  
pp. 114-121
Author(s):  
Marco Giraldi ◽  
Saverio Paltrinieri ◽  
Paola Scarpa
Keyword(s):  
Chronic Kidney Disease ◽  
At Risk ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Sodium Dodecyl ◽  
Electrophoretic Pattern ◽  
Low Molecular Weight ◽  
Tubular Proteinuria ◽  
Exact Test ◽  
Electrophoretic Patterns

Objectives The purpose of this study was to describe the electrophoretic patterns of proteinuria in cats at risk of and cats with chronic kidney disease (CKD), and to investigate whether the presence of high-molecular-weight (HMW) and low-molecular-weight (LMW) proteins were associated with CKD, proteinuria and/or disease progression. Methods Healthy cats at risk of developing renal disease (n = 17) and cats affected with CKD at different stages (n = 22) were prospectively enrolled and sampled over time. Seventy urine samples were included and assayed with a commercially available sodium dodecyl sulfate–agarose gel electrophoresis (SDS-AGE) method. Each sample (gel lane) was inspected to identify albumin, HMW and LMW proteins, and an electrophoretic pattern (albuminuria, glomerular, tubular, mixed or negative) was assigned accordingly. Fisher’s exact test was used to assess the distribution of HMW and LMW proteins in cats grouped according to International Renal Interest Society stage and to the magnitude of proteinuria, and to assess if HMW and LMW proteins at the time of inclusion were associated with the development and progression of CKD. Results In samples of cats at risk, the most common pattern was glomerular (84.6%); glomerular pattern was also common in cats with CKD (54.2%), although mixed proteinuria and tubular proteinuria were also present (29.5% and 11.4%, respectively). The presence of LMW proteins was associated with CKD ( P <0.0001) and to a urine protein:creatinine ratio >0.2 ( P = 0.025). Both HMW and LMW proteins were not associated with progression of CKD within 6 months (n = 14). Conclusions and relevance Our results showed that HMW proteinuria is common in healthy cats at risk of developing CKD, although the pathological significance needs to be confirmed. The detection of LMW proteins in urine of cats suspected to be affected by CKD, especially in non-azotaemic, non-proteinuric or borderline proteinuric cats, suggests the presence of kidney damage.

Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease

2008 ◽  
Vol 4 (9) ◽  
pp. 488-489 ◽  
Author(s):  
Maurizio Gallieni ◽  
Mario Cozzolino ◽  
Chiara Ronga ◽  
Diego Brancaccio
Keyword(s):  
Chronic Kidney Disease ◽  
Molecular Weight ◽  
Kidney Disease ◽  
Low Molecular Weight ◽  
Low Molecular Weight Heparins

scholarly journals Safety and Efficacy of Rapid (one hour) Single Intravenous Dose Low Molecular Weight Iron Dextran for Treatment of Oral Iron Intolerant Maternal Iron Deficient Anemia

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3356-3356
Author(s):  
Michael Auerbach ◽  
Lilee Wong ◽  
Jessica McClintock ◽  
Steven Lenowitz ◽  
Nicola London ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Post Partum ◽  
Oral Iron ◽  
Low Molecular Weight ◽  
Iron Dextran ◽  
Iron Deficient ◽  
The Mean ◽  
Low Molecular Weight Iron ◽  
Change In Mean

Abstract OBJECTIVE: Determine safety and efficacy of rapid (one hour) intravenous infusion of 1,000 mg low molecular weight iron dextran to pregnant women with moderate to severe iron deficient anemia. INTRODUCTION: Up to 70% of pregnant women to whom oral iron is prescribed report significant gastrointestinal side effects. Intravenous iron is an efficient, but often overlooked, therapeutic alternative. METHODS: We conducted an observational treatment study of 1000 mg low molecular weight iron dextran for moderate to severe iron deficient anemia of pregnancy in 189 consecutive, unselected second and third trimester gravidas intolerant of, or unresponsive to, oral iron. All received an intravenous test dose of approximately 25 mg low molecular weight iron dextran. They were then monitored closely for adverse reactions during the balance of a 60 minute infusion. No premedication was administered unless two or more drug allergies or asthma was present in which case prophylactic intravenous methylprednisolone was administered. All subjects were followed through pregnancy and delivery. Monitored parameters included hemoglobin (Hgb), mean corpuscular volume (MCV), serum ferritin, and percent transferrin saturation. RESULTS: One hundred eighty-nine subjects received a single intravenous dose of 1000 mg low molecular weight iron dextran. No first trimester gravidas were treated. No serious adverse events occurred. Minor, self-limited infusion reactions (myalgias or flushing), occurred in 2% of subjects. The mean number of days from treatment to delivery was 58.6 (range 5-190) days. The change in Hgb was positively correlated with the time from treatment to delivery (r2 =0.17, p=0.0039). The initial Hgb was 10.1 g/dl (SD 1.03, SE 0.07) and at delivery 11.5 g/dl (SD=1.04, SE 0.10), with the mean change from diagnosis to delivery of 1.39 g/dl (p<0.0001). An improvement in Hgb was observed in 174 (92% (Figure 1)). In 110 (58%) the observed increment was 1.00-1.99 g/dl (hemoglobin response) and in 45 (24%) ≥ 2.00 g/dl (hematopoietic response). Second trimester treatment was not associated with a greater improvement in Hgb than third trimester treatment. MCV increased by 3.27 femtoliters (fl) for those treated in the second (p<0.0001), and 1.34 in the third(p<0.0001). The mean increment in MCV for those treated in the second trimester was 1.93 fl higher than those treated in the third (p=0.02). Post-partum data were available on 64 (34%). For this subgroup the mean change in Hgb from diagnosis to delivery was 1.48 g/dl, not significantly different than the observed increment for the entire group of 189. From delivery to post-partum follow-up, an additional Hgb increment of 0.66 g/dl was observed (p<0.0001) consistent with sustained iron repletion and post-partum contraction of plasma volume. The increment in Hgb from diagnosis to delivery and diagnosis to post-partum was similar irrespective of trimester of treatment. Anemia resolved in 95%. CONCLUSION: Administration of a rapid (one hour) single large dose (1000 mg) of intravenous low molecular weight iron dextran is a convenient, effective, well tolerated and safe treatment for maternal iron deficient anemia in women who are intolerant of, or unresponsive to, oral iron. These data are relevant in light of recent publications reporting iron deficient neonates have both delayed growth and development and a statistically significant increment in both cognitive and behavioral abnormalities persisting up to ten years after iron repletion. Figure 1. Change in mean hemoglobin concentration (g/dL) +/- SE from diagnosis to delivery to postpartum follow up. Figure 1. Change in mean hemoglobin concentration (g/dL) +/- SE from diagnosis to delivery to postpartum follow up. Disclosures Off Label Use: Total dose infusion of low molecular weight iron dextran is off label.

Sign in / Sign up

Export Citation Format

Share Document